Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Ani Pharmaceuticals (ANIP) Short-Term Debt issuances (2017 - 2021)

Ani Pharmaceuticals' Short-Term Debt issuances history spans 5 years, with the latest figure at $262.0 million for Q4 2021.

On a quarterly basis, Short-Term Debt issuances rose 1846.88% to $262.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $286.0 million, a N/A change, with the full-year FY2021 number at $286.0 million, changed N/A from a year prior.
Short-Term Debt issuances hit $262.0 million in Q4 2021 for Ani Pharmaceuticals, up from $24.0 million in the prior quarter.
Over the last five years, Short-Term Debt issuances for ANIP hit a ceiling of $262.0 million in Q4 2021 and a floor of -$15.0 million in Q4 2020.
Historically, Short-Term Debt issuances has averaged $51.8 million across 3 years, with a median of $19.5 million in 2020.
The widest YoY moves for Short-Term Debt issuances: up 1846.88% in 2021, down 1846.88% in 2021.
Tracing ANIP's Short-Term Debt issuances over 3 years: stood at -$5.0 million in 2017, then tumbled by 200.0% to -$15.0 million in 2020, then surged by 1846.88% to $262.0 million in 2021.
Business Quant data shows Short-Term Debt issuances for ANIP at $262.0 million in Q4 2021, $24.0 million in Q2 2021, and -$15.0 million in Q4 2020.